- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Biomind Labs Inc: Biomind begins trading on CSE | 2 | Stockwatch | ||
| 11.08. | Canadian Securities Exchange (CSE): Canadian Securities Exchange Welcomes Listing of Biomind Labs Inc. | 415 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Biomind Labs Inc. ("Biomind" or the "Company"). The... ► Artikel lesen | |
| 11.08. | XFRA NEW INSTRUMENTS AVAILABLE ON 11.08.2026 | 292 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.08.2026
Aktien
1 US0906842002 BioStem Technologies... ► Artikel lesen | |
| 07.08. | CSE Bulletin: New Listing - Biomind Labs Inc. (BMND) | 96 | Newsfile | Le 7 août/August 2026
The common shares of Biomind Labs Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the listing date.
Biomind... ► Artikel lesen | |
| 06.08. | Biomind Labs Inc: Biomind Labs to be delisted from Cboe Canada | 1 | Stockwatch | ||
| 06.08. | Biomind Labs Inc.: Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada | 545 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs... ► Artikel lesen | |
| 03.07. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 02.06. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| BIOMIND LABS Aktie jetzt für 0€ handeln | |||||
| 21.04. | Biomind Labs Inc: Biomind cheers executive order for psychedelic research | 3 | Stockwatch | ||
| 20.04. | Biomind Labs Inc.: Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States | 433 | ACCESS Newswire | A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20... ► Artikel lesen | |
| 27.01. | Biomind Labs Inc.: Biomind Labs Announces CAD $2.52 Million Private Placement Financing | 519 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 27.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 27.01.2026 | 241 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 27.01.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 27.01.2026ISIN NameDE000HEL0GB7 LB.HESS.THR.CARRARA04S/25XS2576250448... ► Artikel lesen | |
| 03.12.25 | Biomind Labs Inc.: Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood | 433 | ACCESS Newswire | BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 01.12.25 | XFRA 3XI: WIEDERAUFNAHME/RESUMPTION | 314 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 25.11.25 | Biomind Labs Inc.: Biomind Labs Announces Revocation of Cease Trade Order | 552 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked... ► Artikel lesen | |
| 18.11.25 | Biomind Labs Inc.: Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board | 579 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AAP IMPLANTATE | 1,640 | -3,53 % | aap Implantate: Cornelius Fink und Nicole Kassel neu im Vorstand | Bei aap Implantate kommt es zu Veränderungen im Vorstand. CEO Rubino Di Girolamo wird sein Amt zum 31. Dezember 2026 im Einvernehmen mit dem Aufsichtsrat niederlegen und vorzeitig aus dem Vorstand ausscheiden.... ► Artikel lesen | |
| CLEARMIND MEDICINE | 0,778 | -1,58 % | Clearmind Medicine Inc.: Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. | Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins Vancouver, Canada, Sept.... ► Artikel lesen | |
| CG ONCOLOGY | 78,25 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| QIAGEN | 38,695 | +0,74 % | Qiagen sorgt für Gesprächsstoff, Rheinmetall bleibt unter Druck, Nvidia zeigt sich freundlicher und Siemens Energy profitiert von neuer Zuversicht im KI-Segment | Die Zinserhöhung der Fed sowie die Aussicht auf weitere Zinsschritte in der nahen Zukunft scheinen die Märkte erstaunlich schnell verdaut zu haben. Statt weiterer Kursstürze gab es am Donnerstag dann... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,975 | +0,13 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| NURIX THERAPEUTICS | 25,410 | 0,00 % | Nurix auf Morgan Stanley Healthcare-Konferenz: Roche-Deal als Wachstumstreiber | ||
| ARRIVENT BIOPHARMA | 29,740 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| OBSIDIAN THERAPEUTICS | 17,330 | 0,00 % | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,990 | -0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 299,10 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,260 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,910 | +0,06 % | UBS reiterates Summit Therapeutics stock rating on trial data | ||
| MODERNA | 150,76 | -0,04 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| ERASCA | 15,035 | -0,03 % | Propanc Biopharma, Inc.: Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | ||
| PARABILIS MEDICINES | 36,940 | +0,03 % | Parabilis auf Morgan-Stanley-Konferenz: Umfassende Strategie für Beta-Catenin-Plattform |
BIOMIND LABS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,07 % bei einem Aktienkurs von 0,378 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMIND LABS INC finden Sie auf Wallstreet Online.